The common hypothesis proposes that antibodies against MSP-1 could prevent the infection of red blood cells, which has been partially demonstrated in a study with an MSP-1 recombinant antigen tested in the Aotus monkey model, and its effectiveness was also dependent on the adequate selection of an adjuvant system in the vaccine formulation [112]. Here, ATAD1 is linked to infection.